Institut de Cancérologie de l'Ouest, Nantes, France; Centre Hospitalier Départemental Vendée, La Roche Sur Yon, France.
Centre Hospitalier Universitaire, Nantes, France.
Int J Radiat Oncol Biol Phys. 2024 Nov 1;120(3):783-795. doi: 10.1016/j.ijrobp.2024.04.019. Epub 2024 Apr 27.
Osteoradionecrosis (ORN) of the mandible remains a significant complication in the intensity modulated radiation therapy (IMRT) era. Dental dose cannot be predicted from heterogeneous IMRT dose distributions; mandibular dose metrics cannot guide dentist avulsion decisions in high-risk ORN situations. Using a mapping tool to report dental root dose, avulsions, and ORN sites, we re-examined ORN risk factors in a case-control study.
From 2008 to 2019, 897 consecutive patients with oral cavity/oropharynx or unknown primary cancer undergoing IMRT were analyzed to identify ORN cases. These were matched (1 ORN/2 controls) retrospectively for tumor location, surgery, and tobacco consumption in a monocentric case-control study. Univariate and multivariate analyses integrated ORN factors and accurate dental dose data (grouped into 4 mandibular sectors). Generalizability was investigated in a simulated population database.
A total of 171 patients were included. The median follow-up was 5.2 and 4.5 years in the ORN and control groups, respectively. The median time to ORN was 12 months. In univariate analysis, post-IMRT avulsions at the ORN site (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.5-8.9; P = .005), tumor laterality (HR, 4.4; 95% CI, = 1.4-14, P = .01), mean mandibular dose (HR, 1.1; 95% CI, = 1.01-1.1; P = .018) and mean dose to the ORN site (HR, 1.1; 95% CI, = 1.1-1.2; P < .001) correlated with higher ORN risk. In multivariate analysis, mean dose to the ORN site (HR, 1.1; 95% CI, = 1.1-1.2; P < .001) and post-IMRT avulsions at the ORN site (HR, 4.6; 95% CI, = 1.5-14.7; P = .009) were associated with ORN. For each increase in gray in dental dose, the ORN risk increased by 12%. Simulations confirmed study observations.
Dental dose and avulsions are associated with ORN, with a 12% increase in risk with each additional gray. Accurate dose information can help dentists in their decisions after IMRT.
在调强放疗(IMRT)时代,下颌骨放射性骨坏死(ORN)仍然是一个严重的并发症。从不均匀的调强放疗剂量分布中无法预测牙剂量;下颌骨剂量指标不能指导牙医在高危 ORN 情况下进行拔牙决定。我们使用一种映射工具来报告牙齿根部剂量、拔牙和 ORN 部位,在一项病例对照研究中重新检查了 ORN 的危险因素。
2008 年至 2019 年,对 897 例接受口腔/口咽或不明原发灶癌症 IMRT 的连续患者进行分析,以确定 ORN 病例。这些病例在单中心病例对照研究中按肿瘤位置、手术和吸烟情况进行回顾性匹配(1 例 ORN/2 例对照)。在多变量分析中,将 ORN 因素和准确的牙齿剂量数据(分为 4 个下颌骨区)整合在一起。在模拟人群数据库中进行了推广性研究。
共纳入 171 例患者。ORN 组和对照组的中位随访时间分别为 5.2 年和 4.5 年。ORN 的中位发病时间为 12 个月。单因素分析显示,ORN 部位放疗后拔牙(危险比[HR] = 3.6;95%置信区间[CI] = 1.5-8.9;P =.005)、肿瘤侧别(HR,4.4;95%CI,= 1.4-14,P =.01)、下颌骨平均剂量(HR,1.1;95%CI,= 1.01-1.1;P =.018)和 ORN 部位平均剂量(HR,1.1;95%CI,= 1.1-1.2;P <.001)与更高的 ORN 风险相关。多变量分析显示,ORN 部位的平均剂量(HR,1.1;95%CI,= 1.1-1.2;P <.001)和 ORN 部位放疗后的拔牙(HR,4.6;95%CI,= 1.5-14.7;P =.009)与 ORN 相关。牙剂量每增加 1 戈瑞,ORN 风险增加 12%。模拟验证了研究观察结果。
牙剂量和拔牙与 ORN 相关,每增加 1 戈瑞,风险增加 12%。准确的剂量信息可以帮助牙医在 IMRT 后做出决策。